Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
66 67 Next >
Analyst Expectations For Bristol-Myers Squibb's Future
Via Benzinga
After A Bruising 2023, Bristol-Myers Squibb Forges A Risky M&A Strategy
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
H.C. 
Via Benzinga
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
Via Benzinga
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower. 
Via Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Rayzebio, Inc.
Via GlobeNewswire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks. 
Via Talk Markets
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
These two biotech stocks could be poised for a trend reversal. 
Via The Motley Fool
What To Do With High-Flying Tech At The Start Of 2024?
Here, I will do two things. First, I will look at the macro backdrop at the start of 2024, and secondly I will run through the portfolio, how it is doing, and what changes I have made, or intend to... 
Via Talk Markets
Dow Edges Lower; Nike Sales Miss Estimates
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
HBM Gets Health Boost From Drug Licensing Deals
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
Gold Moves Higher; US Consumer Sentiment Improves In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill 
Via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Friday Session
Via Investor Brand Network
Exposures COVID-19
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition... 
Via Benzinga
Topics Stocks
Exposures US Equities
Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics
Via Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n 
Via Benzinga
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis. 
Via Investor's Business Daily
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
From Karuna Therapeutics, Inc.
Via Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.